Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for albuminuria reduction in adults with type 2 diabetes
NL-OMON40930Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change from baseline in 24-hour albuminuria with dapagliflozin relative to placebo after 6 weeks. Started Aug 2014; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40930.